Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting
MesoC2, originally developed using Nona's proprietary Harbour Mice® and integrated ADC platforms, was licensed to Pfizer in December 2023 under a global rights agreement. Pfizer is currently evaluating the ADC in a Phase 1, open-label study in patients with advanced solid tumors, including mesothelioma, platinum-resistant ovarian cancer (PROC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), endometrial cancer (EC), and colorectal cancer (CRC).
Poster Presentation at the 2025 ASCO Annual MeetingTitle: A phase 1 study to evaluate the safety and tolerability of the antibody–drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumorsAbstract Number: TPS3163Poster Board Number: 475aSession Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor BiologySession Date and Time: 02 June 2025; 1:30 PM-4:30 PM (CDT)
Key Highlights from the Presentation:
MesoC2 is an ADC composed of a human IgG1 anti-MSLN monoclonal antibody conjugated to a cleavable tripeptide linker carrying a topoisomerase 1 inhibitor (TOP1i) payload (average drug-to-antibody ratio of 8).
MesoC2 has shown potent antitumor efficacy in in vitro assays and xenograft models and an acceptable safety profile in cynomolgus monkeys.
The Phase 1 trial (NCT06466187) will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy per RECIST v1.1 criteria of MesoC2 in up to 365 patients across dose escalation, optimization, and expansion cohorts.
"We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies," said Dr. Jingsong Wang, Chairman of Nona Biosciences. "The initiation of this Phase 1 trial marks a significant milestone in our collaboration and underscores our shared commitment to addressing unmet needs in oncology."
Pfizer's presentation at the 2025 ASCO Annual Meeting will provide further insights into the trial design. Additional details on the study can be found at ClinicalTrials.gov (NCT06466187).
About MesoC2 (HBM9033/PF-08052666)
MesoC2 (HBM9033/PF-08052666) is an ADC drug that targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully human monoclonal antibody (mAb) in MesoC2 is derived from the Harbour Mice® platform and possesses well-tuned properties, exhibiting reduced binding to soluble MSLN while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb was created to enhance potency in various preclinical tumor models with differing MSLN expression levels, positioning MesoC2 as a potential globally best-in-class therapeutic option.
About Nona Biosciences
Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team.
Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: www.nonabio.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nona-biosciences-collaboration-partner-pfizer-announces-presentation-of-phase-1-clinical-study-design-on-mesoc2-an-msln-targeting-adc-at-the-2025-asco-annual-meeting-302464006.html
SOURCE Nona Biosciences
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025
ALISO VIEJO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 633359. The call will also be broadcast live in listen-only mode via a link on the company's investor relations website at An archived recording of the call will be available through the same link shortly after its completion. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the 'LAL'), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at Company Contact:Shelley B. ThunenChief Financial Officersthunen@ Investor Relations Contact:Oliver MoravcevicVP, Investor Relationsomoravcevic@
Yahoo
21 minutes ago
- Yahoo
Exactech Reaches Consensual Agreement with Unsecured Creditors Committee, Completes Court Filing of Amended Plan
Plan Confirmation and Sale Approval Court Date Expected in Early September GAINESVILLE, Fla., July 24, 2025 /PRNewswire/ -- Exactech, a global medical technology leader, has filed its updated plan of reorganization with the Court, having reached agreement with the Unsecured Creditors Committee (UCC) on details of a consensual plan to accompany the sale of its assets to a new ownership group. Court confirmation of the final plan and approval of the sale is anticipated in early September. The proposed plan was amended to include a new trust structure that will allow general unsecured claimants, including litigation plaintiffs, to continue asserting claims through the trust as it pursues recoveries from non-debtor parties. Additionally, Exactech will receive approximately $60 million of additional financing (for a total of approximately $150 million), provided by Exactech's proposed new owners, to ensure adequate funding as the company continues business as usual operations during the remainder of the proceedings. After the Court confirms the final plan and approves the sale, the company's new owners - which include Strategic Value Partners, LLC (together with its affiliates, "SVP"), Stellex Capital Management, LLC, and Greywolf Capital Management LP - will acquire substantially all of Exactech's operations and assets free and clear, forming a new company strategically positioned for long-term success executing its mission to be the leading surgeon partner in orthopedics. "This agreement represents a significant milestone on the path to Court approval of our plan of reorganization and emergence under new ownership," said Exactech President and CEO Darin Johnson. "We look forward to the Court's approval of the sale and confirmation of the plan over the next several weeks. Throughout this process, we have continued to develop and provide high-quality medical devices for our surgeons and their patients, and we will accelerate this progress as we emerge with a stronger foundation for long-term growth in partnership with our new owners." David Molton, counsel for the Unsecured Creditors Committee, shared that "the UCC, in its efforts to obtain a fair recovery for claimants, appreciates the positive coordination with the new owners and management in developing a consensual plan that keeps litigation claims against certain non-debtor parties in play and, at the same time, ensures that business operations are stewarded forward under new ownership." The UCC encourages its constituents to vote in favor of the amended plan so that the court proceedings can conclude. SVP, Stellex and Greywolf collectively have $29 billion in assets under management and extensive operational expertise in the medical technology and device manufacturing industries. About ExactechExactech is a global medical technology leader that empowers orthopaedic surgeons with innovative implants, surgical instruments and the Active Intelligence® (AI) ecosystem of smart technologies to give patients EXACTLY what they need to regain mobility. Visit for more information and connect with us on LinkedIn, Vumedi, YouTube, Instagram and X. About SVPSVP is a global alternative investment firm that focuses on special situations, private equity, opportunistic credit and financing opportunities. The firm uses a combination of sourcing, financial and operational expertise to unlock value in its portfolio companies. Today SVP manages approximately $22 billion in assets under management, and since inception, has invested more than $50 billion of capital, including more than $18 billion in Europe. The firm, established by Victor Khosla in 2001, has over 200 employees, including more than 100 investment professionals, across its main offices in Greenwich (CT) and London, and a presence in Tokyo. Learn more at About Stellex Capital Management, LLCWith offices in New York, Pittsburgh, Detroit, and London, Stellex Capital is a private equity firm with over $3.9 billion in assets under management. Stellex seeks to identify and deploy capital in opportunities that stand to benefit from its operationally focused and hands-on approach to investing. Portfolio companies are supported by Stellex's industry knowledge, operating capabilities, network of senior executives, strategic insights, and access to capital. About Greywolf LPFounded in 2003, Greywolf Capital Management LP ("Greywolf" or the "Firm") is a registered investment adviser with over $3 billion in assets under management allocated across our Distressed/Special Situations, CLO Credit and Hard Asset Strategies. Our accomplished and cohesive team of 32 includes 14 dedicated investment professionals. At Greywolf, we combine the expertise developed over our history with time-tested portfolio management skills to offer attractive, risk-adjusted returns over the long-term with little correlation to the broad based markets. The Firm has earned a reputation for its commitment to integrity, transparency and alignment as a true partner with our investors. View original content to download multimedia: SOURCE Exactech, Inc Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025
MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ('Sight Sciences' or the 'Company'), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the second quarter ended June 30, 2025, after the market close on Thursday, August 7, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event. About Sight Sciences Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world's leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company's TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit for more information. Sight Sciences, the Sight Sciences logo, TearCare, and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories. © 2025 Sight Sciences. All rights reserved. Media contact:pr@ Investor contact:Philip TaylorGilmartin in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
